---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028686"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2026-06-15T20:05:40+00:00"
generated_at: "2026-06-15T20:15:27.570888+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience reports Q3 net loss of $624k; CEO Bartlett to retire July 31, Kitchell to succeed

## Summary
- Q3 net product sales $506k (+3.5% YoY); net loss $624k vs $580k YoY; EPS ($0.01).
- Nine-month net product sales $1.66M (+15.4% YoY); net loss $1.87M vs $2.07M YoY.
- CEO Robert Bartlett retiring July 31, 2026; President Jeff Kitchell appointed CEO effective Aug 1.
- Director Bernard Blotner leaving board due to health; no replacement named.

## SEC filing metadata
- accession: 0001493152-26-028686
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2026-06-15T20:05:40+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/0001493152-26-028686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028686
- JSON: https://secwatch.observer/filing/0001493152-26-028686.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028686.txt

## Key facts
- Earnings Releases
  PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2026 results: revenue $1,656,000, net income $1,873,000, EPS ($0.02).
  - Period: the nine months ended April 30, 2026
  - Revenue: $1,656,000
  - Net income: $1,873,000
  - EPS: ($0.02)
  - Result: reported results
  source text: per share was ($0.01) for the fiscal third quarters ended April 30, 2026 and 2025, respectively. Summary of Results of Operations – Prior Nine Months ● Net product sales were $1,656,000 and $1,435,000 for the nine months ended April 30, 2026 and 2025, respectively. The $221,000 increase was attributable to higher sales across our end-user network. ● Net loss
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/0001493152-26-028686-index.htm
- Earnings Releases
  PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2026 results: revenue $506,000, net income $624,000, EPS ($0.01).
  - Period: the fiscal third quarter ended April 30, 2026
  - Revenue: $506,000
  - Net income: $624,000
  - EPS: ($0.01)
  - Result: reported results
  source text: ) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2026. Summary of Results of Operations – Third Quarter ● Net product sales were $506,000 and $489,000 for the fiscal third quarters ended April 30, 2026 and 2025, respectively. The $17,000 increase was attributable to higher sales across our distribution network. ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/0001493152-26-028686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.